Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Hyperion DeFi, Inc. (HYPD : NSDQ)

• Company Description    Eyenovia, Inc. is a clinical stage biopharmaceutical company which engages in developing therapeutics for the treatment of prominent eye diseases primarily in the United States. Its product portfolio includes MicroProst, MicroStat, MicroTears and MicroPine which are in clinical stage. Eyenovia, Inc. is based in New York. Number of Employees: 14

• Price / Volume Information    Yesterday's Closing Price: $6.44 Daily Weekly Monthly 20 Day Moving Average: 531,546 shares Shares Outstanding: 6.96 (millions) Market Capitalization: $44.82 (millions) Beta: 2.57 52 Week High: $41.06 52 Week Low: $0.85 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -19.80% -21.90% 12 Week -10.56% -14.26% Year To Date -44.86% -51.81%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 23461 SOUTH POINT DRIVE SUITE 390 - LAGUNA HILLS,CA 92653 USA ph: 833-393-6684 fax: - eric@lifesciadvisors.com http://www.eyenoviabio.com

• General Corporate Information    Officers Michael Rowe - Chief Executive Officer Tsontcho Ianchulev - Director Rachel Jacobson - Director Charles E. Mather IV - Director Ram Palanki - Director Peer Information Hyperion DeFi, Inc. (CORR.) Hyperion DeFi, Inc. (RSPI) Hyperion DeFi, Inc. (CGXP) Hyperion DeFi, Inc. (BGEN) Hyperion DeFi, Inc. (GTBP) Hyperion DeFi, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 30234E203 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/13/25 Share - Related Items Shares Outstanding: 6.96 Most Recent Split Date: 2.00 (0.01:1) Beta: 2.57 Market Capitalization: $44.82 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.97 Price/Cash Flow: - Price / Sales: 658.18 EPS Growth vs. Year Ago Period: 82.64% vs. Previous Quarter: -57.23% Sales Growth vs. Year Ago Period: 200.00% vs. Previous Quarter: -46.61% ROE 09/30/25 - - 06/30/25 - -876.25 03/31/25 - - ROA 09/30/25 - - 06/30/25 - -181.67 03/31/25 - -316.90 Current Ratio 09/30/25 - - 06/30/25 - 0.91 03/31/25 - 0.34 Quick Ratio 09/30/25 - - 06/30/25 - 0.91 03/31/25 - 0.34 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - -59,853.44 Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - -62,238.41 Pre-Tax Margin 09/30/25 - - 06/30/25 - -88,743.27 03/31/25 - -62,238.41 Book Value 09/30/25 - - 06/30/25 - 6.67 03/31/25 - -3.43 Inventory Turnover 09/30/25 - - 06/30/25 - 4.36 03/31/25 - 2.47 Debt-to-Equity 09/30/25 - - 06/30/25 - 0.20 03/31/25 - - Debt-to-Capital 09/30/25 - - 06/30/25 - 16.75 03/31/25 - -

Powered by Zacks Investment Research ©